1. SO-003Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. (2nd July 2019) Authors: Matos, I; Goyal, L; Cleary, J; Voss, M; Oh, D; Bernstam, F Meric; Ng, C; Iyer, G; Ishii, N; Hu, Y; Chessex, A Vaslin; Pokorska-Bocci, A; Nicolas, V; Kirpicheva, Y; Zanna, C; Flaherty, K; Tabernero, J; Hyman, D Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SO-010Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors. (2nd July 2019) Authors: Garralda, E; Fiedler, W; Matos, I; Rolling, C; Kebenko, M; Klinghammer, K; Conte, G; Raspagliesi, F; Habel, B; Baumeister, H; Ochsenreither, S; Zurlo, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Early-drug development in the era of immuno-oncology: are we ready to face the challenges?. (26th June 2018) Authors: Ochoa de Olza, M; Oliva, M; Hierro, C; Matos, I; Martin-Liberal, J; Garralda, E Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1727 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Early evolutionary divergence between papillary and anaplastic thyroid cancers. (10th April 2018) Authors: Capdevila, J; Mayor, R; Mancuso, F M; Iglesias, C; Caratù, G; Matos, I; Zafón, C; Hernando, J; Petit, A; Nuciforo, P; Cameselle-Teijeiro, J M; Álvarez, C; Recio, J A; Tabernero, J; Matias-Guiu, X; Vivancos, A; Seoane, J Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1454 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 143PTumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT). (23rd October 2018) Authors: Martin-Liberal, J; Pagliuca, F; Hierro, C; Viaplana, C; Muñoz Couselo, E; Capdevila, J; Matos, I; Fariñas Madrid, L; Zamora, E; Braña Garcia, I; Elez Fernandez, E; Ochoa De Olza Amat, M; Azaro, A; Alsina, M; Vieito Villar, M; Fasani, R; Tabernero, J; Garralda, E; Dienstmann, R; Nuciforo, P G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 376PDImpact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors. (23rd October 2018) Authors: Benítez Montañez, J C; Vieito Villar, M; Hierro, C; Gonzalez Rodriguez, M; Matos, I; Braña Garcia, I; Suarez Rodriguez, C; Martinez Saez, E A; Perez-Gago, M C; Morales-Barrera, R; Ortiz, C; Suarez, C; Maldonado, X; Martinez-Ricarte, F; Auger, C; Azaro, A; Dienstmann, R; Carles, J; Garralda, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 92PVall d'Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI). (23rd October 2018) Authors: Hierro, C; Matos, I; Martin-Liberal, J; Ochoa De Olza Amat, M; Felip, E; Costa Rivas, M; Vieito Villar, M; Brana, I; Azaro, A; Perez-Gago, M C; Gros, A; Carles, J; Oaknin, A; Macarulla, T; Saura, C; pardo, N; Muñoz-Couselo, E; Tabernero, J; Dienstmann, R; Garralda, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 1510TiPThe GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. (23rd October 2018) Authors: Garralda, E; van Hoef, M; Ochsenreither, S; Gianni, L; Lorusso, D; Fiedler, W; Keilholz, U; Klinghammer, K; Dicke, C; Kebenko, M; Matos, I; Tabernero, J; Raspagliesi, F; Del Conte, G; Habel, B; Baumeister, H; Zurlo, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Early evolutionary divergence between papillary and anaplastic thyroid cancers. (13th August 2019) Authors: Capdevila, J; Mayor, R; Mancuso, F M; Iglesias, C; Caratú, G; Matos, I; Zafón, C; Hernando, J; Petit, A; Nuciforo, P; Cameselle-Teijeiro, J M; Álvarez, C V; Recio, J A; Tabernero, J; Matias-Guiu, X; Vivancos, A; Seoane, J Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1843 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗